DBV Technologies (DBVT) Net Equity Issued and Repurchased (2020 - 2026)
DBV Technologies (DBVT) posted Net Equity Issued and Repurchased of -$100000.0 for Q2 2026, down 100.11% sequentially from $89.1 million in Q1 2026, and down 100.09% YoY from $116.9 million in Q2 2025.
DBV Technologies (DBVT) Net Equity Issued and Repurchased (2020 - 2026) Analysis & Trends
DBV Technologies has reported Net Equity Issued and Repurchased for 7 years, with the latest figure at -$100000.0 in Q2 2026.
- Quarterly Net Equity Issued and Repurchased fell 100.09% year-over-year to -$100000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $247.8 million (up 110.84% YoY) and the FY2025 annual result came in at $275.7 million, up 43386.75% from the prior year.
- Net Equity Issued and Repurchased fell to -$100000.0 in Q2 2026 per DBVT's latest filing, from $89.1 million in the prior quarter.
- Over five years, Net Equity Issued and Repurchased peaked at $195.3 million in Q2 2022 and troughed at -$864000.0 in Q3 2023.
- A 5-year average of $50.8 million and a median of $36000.0 in 2025 frame the typical range for Net Equity Issued and Repurchased.
- The sharpest annual moves came in 2022 and 2026: Net Equity Issued and Repurchased jumped 25866.76% in 2022, then slumped 100.09% in 2026.
- Over 5 years, Net Equity Issued and Repurchased stood at -$261000.0 in 2022, then soared by 107.28% to $19000.0 in 2023, then surged by 3236.84% to $634000.0 in 2024, then jumped by 24942.59% to $158.8 million in 2025, then tumbled by 100.06% to -$100000.0 in 2026.
- According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered -$100000.0, $89.1 million, and $158.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | DBV Technologies | 6.08 Bn | 5.90 Bn | - | -100,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -100,000.00 |
| Jun 30, 2026 | -100,000.00 |
| Mar 31, 2026 | 89.10 Mn |
| Mar 31, 2026 | 89.10 Mn |
| Dec 31, 2025 | 158.77 Mn |
| Dec 31, 2025 | 158.77 Mn |
| Sep 30, 2025 | 36,000.00 |
| Sep 30, 2025 | 36,000.00 |
| Jun 30, 2025 | 116.90 Mn |
| Jun 30, 2025 | 116.90 Mn |
| Dec 31, 2024 | 634,000.00 |
| Dec 31, 2024 | 634,000.00 |
| Dec 31, 2023 | 19,000.00 |
| Dec 31, 2023 | 19,000.00 |
| Sep 30, 2023 | -864,000.00 |
| Sep 30, 2023 | -864,000.00 |
| Dec 31, 2022 | -261,000.00 |
| Dec 31, 2022 | -261,000.00 |
| Sep 30, 2022 | -538,000.00 |
| Sep 30, 2022 | -538,000.00 |